2011NICE肺癌診治指南
《2011NICE肺癌診治指南》內(nèi)容簡(jiǎn)介：
Since publication of NICE clinical guideline 24 in 2005, a number of newsystemic therapies have been granted a marketing authorisation by theEuropean Medicines Agency for use in people with NSCLC. NICE haspublished technology appraisals for pemetrexed, gefitinib and erlotinib. Othertechnology appraisals are in development.
《2011NICE肺癌診治指南》內(nèi)容預(yù)覽：
This guidance updates and replaces NICE clinical guideline 24 （publishedFebruary 2005）。
New and updated recommendations are included on communication,diagnosis and staging, selection of patients with non-small-cell lung cancer（NSCLC） for treatment with curative intent, surgery with curative intent forNSCLC, smoking cessation, combination treatment for NSCLC, treatment forsmall-cell lung cancer （SCLC）， managing endobronchial obstruction,managing brain metastases, and follow-up and patient perspectives.
點(diǎn)擊下載***：《2011NICE肺癌診治指南》
本站所注明來源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉(zhuǎn)載的媒體或個(gè)人可與我們
聯(lián)系z(mì)lzs@120.net，我們將立即進(jìn)行刪除處理
熱點(diǎn)圖文
-
2013我國胰腺囊性腫瘤共識(shí)意見草案
本共識(shí)意見（草案）依據(jù)我國胰腺囊性腫瘤的最近研究，并參考國際相關(guān)指南和研究...[詳細(xì)]
-
2013NCCN結(jié)直腸癌指南
在美國，結(jié)直腸癌發(fā)病率占所有癌癥的第四位，而死亡率為第二位。2012年估計(jì)...[詳細(xì)]
